BRAIN and NERVE－神経研究の進歩67巻11号

2015年11月発行

記事購入ページに移動

増大特集 ギラン・バレー症候群のすべて—100年の軌跡

急性発症CIDP

著者： 神林隆道¹ 園生雅弘¹

所属機関： ¹帝京大学医学部附属病院神経内科

ページ範囲：P.1388 - P.1396

慢性炎症性脱髄性多発根ニューロパチー（CIDP）の中には，ギラン・バレー症候群（GBS）様の発症経過を呈する，急性発症CIDPが存在する。急性発症CIDPは，GBSの亜型である急性炎症性脱髄性ポリニューロパチー（AIDP）と臨床的，電気生理学的にも類似所見を呈し，発症初期の鑑別に難渋する。初期にGBSと診断されていても，発症4週以降も症状が進行する例や，単相性経過がみられない例では，急性発症CIDPの可能性を考慮すべきである。

参考文献

1) Dalakas MC: Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol 7: 507-517, 2011

2) Austin JH: Recurrent polyneuropathies and their corticosteroid treatment; with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone. Brain 81: 157-192, 1958

3) Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, et al: Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 50: 621-637, 1975

4) Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 41: 617-618, 1991

5) Saperstein DS, Katz JS, Amato AA, Barohn RJ: Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 24: 311-324, 2001

6) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 10: 220-228, 2005

7) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision. J Peripher Nerv Syst 15: 1-9, 2010

8) 福島和広, 池田修一: 非典型的CIDP. Clinical Neuroscience 32: 309-312, 2014

9) Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, et al: Guillain-Barre syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 118: 597-605, 1995

10) Mori K, Hattori N, Sugiura M, Koike H, Misu K, et al: Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS. Neurology 58: 979-982, 2002

11) Quek AM, Soon D, Chan YC, Thamboo TP, Yuki N: Acute-onset chronic inflammatory demyelinating polyneuropathy with focal segmental glomerulosclerosis. J Neurol Sci 341: 139-143, 2014

12) McCombe PA, Pollard JD, McLeod JG: Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 110: 1617-1630, 1987

13) Gorson KC, Allam G, Ropper AH: Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 48: 321-328, 1997

14) Van der Meché FG, Van Doorn PA, Meulstee J, Jennekens FG, Centre GB-cgotDNRS: Diagnostic and classification criteria for the Guillain-Barré syndrome. Eur Neurol 45: 133-139, 2001

15) Hughes RA, Cornblath DR: Guillain-Barré syndrome. Lancet 366: 1653-1666, 2005

16) Winer JB: Guillain-Barré syndrome. BMJ 337: a671, 2008

17) Odaka M, Yuki N, Hirata K: Patients with chronic inflammatory demyelinating polyneuropathy initially diagnosed as Guillain-Barré syndrome. J Neurol 250: 913-916, 2003

18) Walgaard C, Lingsma HF, Ruts L, van Doorn PA, Steyerberg EW, et al: Early recognition of poor prognosis in Guillain-Barré syndrome. Neurology 76: 968-975, 2011

19) 荻野美恵子, 荻野　裕, 加藤知也, 入江幸子, 金沢直美, 他: Guillain-Barré症候群（GBS）の全国調査　第三次調査. 臨床神経41: 998, 2001

20) Rotta FT, Sussman AT, Bradley WG, Ram Ayyar D, Sharma KR, et al: The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 173: 129-139, 2000

21) McGrogan A, Madle GC, Seaman HE, de Vries CS: The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology 32: 150-163, 2009

22) Meléndez-Vásquez C, Redford J, Choudhary PP, Gray IA, Maitland P, et al: Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy. J neuroimmunol 73: 124-134, 1997

23) Dionne A, Nicolle MW, Hahn AF: Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy. Muscle Nerve 41: 202-207, 2010

24) Winer JB, Hughes RA, Osmond C: A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J Neurol Neurosurg Psychiatry 51: 605-612, 1988

25) 荻野美恵子, 斉藤豊和, 有村公良, 納　光弘: Guillain-Barré症候群の全国調査—第3次調査結果を含めた最終報告—. 厚生労働省特定疾患対策研究事業免疫性神経疾患に関する調査研究班　平成12年度研究報告書. 2001, pp99-101

26) Grand'Maison F, Feasby TE, Hahn AF, Koopman WJ: Recurrent Guillain-Barré syndrome. Clinical and laboratory features. Brain 115: 1093-1106, 1992

27) Wijdicks EF, Ropper AH: Acute relapsing Guillain-Barré syndrome after long asymptomatic intervals. Arch Neurol 47: 82-84, 1990

28) Kusunoki S, Kaida K, Ueda M: Antibodies against gangliosides and ganglioside complexes in Guillain-Barré syndrome: new aspects of research. Biochim Biophys Acta 1780: 441-444, 2008

29) Kuwabara S, Asahina M, Koga M, Mori M, Yuki N, et al: Two patterns of clinical recovery in Guillain-Barré syndrome with IgG anti-GM1 antibody. Neurology 51: 1656-1660, 1998

30) Kaida K, Morita D, Kanzaki M, Kamakura K, Motoyoshi K, et al: Anti-ganglioside complex antibodies associated with severe disability in GBS. J Neuroimmunol 182: 212-218, 2007

31) Csurhes PA, Sullivan AA, Green K, Greer JM, Pender MP, et al: Increased circulating T cell reactivity to GM1 ganglioside in patients with Guillain-Barré syndrome. J Clin Neurosci 12: 409-415, 2005

32) Shahrizaila N, Kokubun N, Sawai S, Umapathi T, Chan YC, et al: Antibodies to single glycolipids and glycolipid complexes in Guillain-Barré syndrome subtypes. Neurology 83: 118-124, 2014

33) Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, et al: Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol 44: 780-788, 1998

34) 国分則人: GBS・CIDPの電気診断. Brain Medical 25: 201-207, 2013

35) Bromberg MB, Albers JW: Patterns of sensory nerve conduction abnormalities in demyelinating and axonal peripheral nerve disorders. Muscle Nerve 16: 262-266, 1993

36) Al-Shekhlee A, Hachwi RN, Preston DC, Katirji B: New criteria for early electrodiagnosis of acute inflammatory demyelinating polyneuropathy. Muscle Nerve 32: 66-72, 2005

37) Rajabally YA, Narasimhan M: The value of sensory electrophysiology in chronic inflammatory demyelinat-ing polyneuropathy. Clin Neurophysiol 118: 1999-2004, 2007

38) Ruts L, Drenthen J, Jacobs BC, van Doorn PA; Dutch GBS Study Group: Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome: a prospective study. Neurology 74: 1680-1686, 2010

39) Anadani M, Katirji B: Acute-Onset chronic inflammatory demyelinating polyneuropathy. An electrodiagnostic study. Muscle Nerve, 2015 Mar 25 ［Epub ahead of print］ doi: 10.1002/mus.24667

40) Kerasnoudis A, Pitarokoili K, Behrendt V, Gold R, Yoon MS: Bochum ultrasound score versus clinical and electrophysiological parameters in distinguishing acute-onset chronic from acute inflammatory demyelinating polyneuropathy. Muscle Nerve 51: 846-852, 2015

41) Rajabally YA, Hiew FL: The value of ultrasonography versus clinical examination in differentiating acute inflammatory demyelinating polyneuropathy from acute-onset chronic inflammatory demyelinating polyneuropathy: The importance of timing. Muscle Nerve 51: 459, 2015

42) Hughes R, Sanders E, Hall S, Atkinson P, Colchester A, et al: Subacute idiopathic demyelinating polyradiculoneuropathy. Arch Neurol 49: 612-616, 1992

43) Oh SJ: Subacute inflammatory demyelinating polyneuropathy: not a new concept. Arch Neurol 51: 234-236, 1994

44) Oh SJ, Kurokawa K, de Almeida DF, Ryan HF, Jr., Claussen GC: Subacute inflammatory demyelinating polyneuropathy. Neurology 61: 1507-1512, 2003

45) Jo HY, Park MG, Kim DS, Nam SO, Park KH: Chronic inflammatory demyelinating polyradiculoneuropathy in children: characterized by subacute, predominantly motor dominant polyeuropathy with a favorable response to the treatment. Acta Neurol Scand 121: 342-347, 2010

46) Ropper AE, Albert JW, Addison R: Limited relapse in Guillain-Barré syndrome after plasma exchange. Arch Neurol 45: 314-315, 1988

47) Osterman PO, Fagius J, Säfwenberg J, Wikström B: Early relapse of acute inflammatory polyradiculoneuropathy after successful treatment with plasma exchange. Acta Neurol Scand 77: 273-277, 1988

48) Kleyweg RP, van der Meché FG: Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry 54: 957-960, 1991

49) Ruts L, van Koningsveld R, van Doorn PA: Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations. Neurology 65: 138-140, 2005

50) Iijima M, Yamamoto M, Hirayama M, Tanaka F, Katsuno M, et al: Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP. Neurology 64: 1471-1475, 2005